MaxCyte Inc (MXCT) - Net Assets
Based on the latest financial reports, MaxCyte Inc (MXCT) has net assets worth $180.28 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($213.48 Million) and total liabilities ($33.20 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are MaxCyte Inc's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $180.28 Million |
| % of Total Assets | 84.45% |
| Annual Growth Rate | N/A |
| 5-Year Change | 520.76% |
| 10-Year Change | N/A |
| Growth Volatility | 234.1 |
MaxCyte Inc - Net Assets Trend (2012–2024)
This chart illustrates how MaxCyte Inc's net assets have evolved over time, based on quarterly financial data. Also explore MaxCyte Inc (MXCT) total assets for the complete picture of this company's asset base.
Annual Net Assets for MaxCyte Inc (2012–2024)
The table below shows the annual net assets of MaxCyte Inc from 2012 to 2024. For live valuation and market cap data, see MaxCyte Inc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $206.25 Million | -11.16% |
| 2023-12-31 | $232.17 Million | -8.58% |
| 2022-12-31 | $253.97 Million | -3.40% |
| 2021-12-31 | $262.90 Million | +691.25% |
| 2020-12-31 | $33.23 Million | +144.27% |
| 2019-12-31 | $13.60 Million | +10.75% |
| 2018-12-31 | $12.28 Million | -37.33% |
| 2017-12-31 | $19.60 Million | +285.50% |
| 2016-12-31 | $5.08 Million | +264.91% |
| 2015-12-31 | $-3.08 Million | -87.14% |
| 2014-12-31 | $-1.65 Million | -6.74% |
| 2013-12-31 | $-1.54 Million | -161.25% |
| 2012-12-31 | $-590.70K | -- |
Equity Component Analysis
This analysis shows how different components contribute to MaxCyte Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 18548390000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.06 Million | 0.51% |
| Other Components | $422.05 Million | 204.63% |
| Total Equity | $206.25 Million | 100.00% |
MaxCyte Inc Competitors by Market Cap
The table below lists competitors of MaxCyte Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Trek Metals Ltd
AU:TKM
|
$84.46 Million |
|
Berenson Acquisition Corp I
NYSE MKT:BACA
|
$84.51 Million |
|
Wellpool Co Ltd
TWO:8424
|
$84.51 Million |
|
ZUARI INDUSTRIES LIMITED
NSE:ZUARIIND
|
$84.51 Million |
|
Union Auction Public Company Limited
BK:AUCT
|
$84.34 Million |
|
Sempio Foods Co
KO:248170
|
$84.33 Million |
|
Say Yenilenebilir Enerji Ekipmanları Sanayi ve Ticaret Anonim Şirketi
IS:SAYAS
|
$84.33 Million |
|
Kingcan Holdings Ltd
TW:8411
|
$84.29 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MaxCyte Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 232,167,000 to 206,251,000, a change of -25,916,000 (-11.2%).
- Net loss of 41,055,000 reduced equity.
- Share repurchases of 459,000 reduced equity.
- Other factors increased equity by 15,598,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-41.05 Million | -19.91% |
| Share Repurchases | $459.00K | -0.22% |
| Other Changes | $15.60 Million | +7.56% |
| Total Change | $- | -11.16% |
Book Value vs Market Value Analysis
This analysis compares MaxCyte Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.45x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-0.01 | $0.88 | x |
| 2013-12-31 | $-0.04 | $0.88 | x |
| 2014-12-31 | $-1.43 | $0.88 | x |
| 2015-12-31 | $-0.07 | $0.88 | x |
| 2016-12-31 | $0.15 | $0.88 | x |
| 2017-12-31 | $0.40 | $0.88 | x |
| 2018-12-31 | $0.24 | $0.88 | x |
| 2019-12-31 | $0.24 | $0.88 | x |
| 2020-12-31 | $0.48 | $0.88 | x |
| 2021-12-31 | $2.90 | $0.88 | x |
| 2022-12-31 | $2.50 | $0.88 | x |
| 2023-12-31 | $2.25 | $0.88 | x |
| 2024-12-31 | $1.97 | $0.88 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MaxCyte Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -19.91%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -106.29%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 1.16x
- Recent ROE (-19.91%) is above the historical average (-28.60%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | -39.30% | 1.78x | 0.00x | $-1.93 Million |
| 2013 | 0.00% | -14.08% | 2.72x | 0.00x | $-803.88K |
| 2014 | 0.00% | -25.64% | 1.14x | 0.00x | $-1.67 Million |
| 2015 | 0.00% | -15.56% | 1.45x | 0.00x | $-1.14 Million |
| 2016 | -65.81% | -27.27% | 0.76x | 3.16x | $-3.85 Million |
| 2017 | -50.61% | -70.91% | 0.45x | 1.60x | $-11.88 Million |
| 2018 | -72.21% | -53.21% | 0.69x | 1.98x | $-10.10 Million |
| 2019 | -94.80% | -59.64% | 0.72x | 2.20x | $-14.26 Million |
| 2020 | -35.56% | -45.15% | 0.51x | 1.56x | $-15.14 Million |
| 2021 | -7.26% | -56.30% | 0.12x | 1.08x | $-45.37 Million |
| 2022 | -9.28% | -53.25% | 0.15x | 1.13x | $-48.97 Million |
| 2023 | -16.33% | -91.85% | 0.15x | 1.16x | $-61.14 Million |
| 2024 | -19.91% | -106.29% | 0.16x | 1.16x | $-61.68 Million |
Industry Comparison
This section compares MaxCyte Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,432,799,891
- Average return on equity (ROE) among peers: -74.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MaxCyte Inc (MXCT) | $180.28 Million | 0.00% | 0.18x | $84.42 Million |
| Abbott Laboratories (ABT) | $24.16 Billion | 9.46% | 0.81x | $155.56 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-13.54K | 0.00% | 0.00x | $21.60 Million |
| Aethlon Medical Inc (AEMD) | $9.29 Million | -84.45% | 0.15x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $105.73 Million | -116.68% | 0.61x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $2.15 Million | -112.84% | 0.45x | $16.04 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $8.60 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $4.22 Million |
| Artivion Inc (AORT) | $89.39 Million | 8.74% | 0.25x | $1.73 Billion |
| Apyx Medical Inc (APYX) | $21.15 Million | 2.82% | 0.30x | $125.55 Million |
About MaxCyte Inc
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based … Read more